Yang Zhao

Sun Pharma

Dr. Zhao received a PhD in Economics from the Johns Hopkins University and have more than 20 years’ experience in the health care industry. She has broad Global and US experience supporting phase II-IV product development in neuroscience, bone and muscle, dermatology, ophthalmology, and oncology. She has supported the product launch and commercialization of Cymbalta, Forteo, Cosentyx, Yonsa, Odomzo, Ilumya, and Infugem.



E-Posters by Yang Zhao
Tildrakizumab efficacy over time stratified by week-28 response levels and by prior biologic use
Tildrakizumab efficacy over time stratified by week-28 response levels and by prior biologic use
Andrew Blauvelt, Howard Sofen, Kim Papp, Melinda Gooderham, Yang Zhao, Alan Mendelsohn, Simon Lowry, Stephen Rozzo, Kristian Reich6